- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases909
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases909
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- PR positive
- EGFR positive
- ER negative
- PD-L1 negative
- PR negative
- EGFR negative
- KRAS positive
- ALK negative
- p16 positive
- BRAF positive
- BRCA1 positive
- BRCA2 positive
- CD20 positive
- IDH positive
- MET positive
- ALK positive
- BRAF negative
- TP53 positive
- ROS1 negative
- CD19 positive
- HLA-A positive
- HR positive
- p16 negative
- IDH negative
- MYC positive
- PALB2 positive
- HLA positive
- MSI-H positive
- PIK3CA positive
- ctDNA positive
- dMMR positive
- ANA positive
- BRCA positive
- HPV negative
- ROS1 positive
- anti-dsDNA positive
- FGFR2 positive
- HPV positive
- MET negative
- ATM positive
- BCR-ABL1 positive
- BRCA1 negative
- CD30 positive
- FLT3 positive
- HBsAg positive
- MGMT negative
- MGMT positive
- RAS positive
- BCL2 positive
- BRCA2 negative
- CCND1 positive
- FGFR3 positive
- L858R positive
- NRAS positive
- PD-1 positive
- RAS negative
- RB1 positive
- TP53 negative
- BCL6 positive
- CFTR positive
- DMD positive
- FGFR positive
- HBV DNA positive
- HLA-A negative
- HbSS positive
- MMR positive
- NF1 positive
- NTRK negative
- PTEN positive
- Philadelphia chromosome positive
- RB1 negative
- RET negative
- RET positive
- del(17p) positive
- ARID1A positive
- CD22 positive
- COL7A1 positive
- Complex karyotype positive
- Ex19del positive
- FLT3 negative
- FMR1 positive
- HLA negative
- MLH1 positive
- MSH2 positive
- MSH6 positive
- MSI-H negative
- NTRK positive
- PD-1 negative
- PIK3CA negative
- PMS2 positive
- SMN1 positive
- STK11 positive
- T790M positive
- TROP2 negative
- TROP2 positive
- anti-Sm positive
- dMMR negative
- p53 positive
- AKT negative
- APP positive
- C5 positive
- CD123 positive
- CDK12 positive
- CEA positive
- CLDN18.2 positive
- EpCAM positive
- FGFR1 positive
- H3K27M positive
- KIT positive
- KMT2A positive
- KRAS negative
- Ki-67 positive
- MDM2 positive
- MSS negative
- MSS positive
- NPM1 positive
- NRAS negative
- PMM2 positive
- PSEN1 positive
- PSEN2 positive
- PTEN negative
- PiZZ positive
- RAD51C positive
- RAD51D positive
- RAF positive
- RF positive
- RUNX1 positive
- SF3B1 positive
- SOD1 positive
- SPINK5 positive
- SRSF2 positive
- TTR positive
- U2AF1 positive
- ZRSR2 positive
- p53 negative
- 11q negative
- 11q positive
- 1p/19q co-deletion positive
- ABCA4 positive
- AKT positive
- ALPL positive
- APC positive
- AR positive
- ASXL1 positive
- Aβ1-42 positive
- BAP1 positive
- BARD1 positive
- BRIP1 positive
- CAG repeat in HTT positive
- CD19 negative
- CD20 negative
- CD30 negative
- CD33 positive
- CD5 positive
- CDH1 positive
- CHEK1 positive
- CHEK2 positive
- COL1A1 positive
- COL1A2 positive
- COL3A1 positive
- D67N positive
- EBV positive
- ER or PR positive
- EZH2 positive
- FANCL positive
- FKRP positive
- FOLR1 positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- HBB positive
- HBV DNA negative
- HBeAg positive
- HCV RNA positive
- HPV16 positive
- HR negative
- HRAS positive
- HRR negative
- HRRm positive
- HbSC positive
- IA2 positive
- IGHV positive
- JAK2 positive
- K70R positive
- KEAP1 positive
- Ki-67 negative
- L210W positive
- L861Q positive
- M41L positive
- MECP2 positive
- MSI negative
- MSI positive
- MTAP positive
- MTOR negative
- Mismatch repair deficiency positive
- NF2 positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- 68Ga-DOTATATE PET/CT Scan
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Therapy (except reconstruction)
- Anti-HER2 Therapy
- Anti-Seizure Medications (up to 2 types)
- Any Number of Prior Systemic Therapy Lines for Locally Advanced Inoperable Tumor
- Any Number of Prior Systemic Therapy Lines for Metastatic Disease
- Any Prior Therapy
- Any Treatment for Pancreatic Cancer
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
6331 trials
Trials Without a Placebo
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to see if bitopertin is effective and safe in treating EPP or XLP in participants aged 12 and above. It will investigate whether bitopertin can increase pain
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare the effects of different types of fluids given during surgery on acid-base balance and electrolytes in young patients. Patients will be randomly assigned to receive either normal saline or hypertonic saline
Efficacy & Safety Awards
No Placebo-Only Group
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial aims to test a combination of interventions, including improving sleep, cognitive exercises, and extended pain relief after heart surgery to reduce confusion, agitation, and decline in cognitive function. These interventions are based
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial will test a new long-acting HIV treatment for people who still have detectable virus levels despite taking oral medication. The study will look at how well the treatment works, how safe it is
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether giving azithromycin along with standard antibiotics to 8,000 women having a cesarean delivery can help reduce infections after childbirth. The study will compare the rates of
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will randomly assign participants to receive either Luminopia dichoptic treatment, Vivid Vision dichoptic treatment, or continued optical correction alone. Participants will be assessed at 9 and 18 weeks
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares two types of radiation therapy for treating cancer that has spread to the brain. One type, called fractionated stereotactic radiosurgery (FSRS), delivers a high dose of radiation over
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Summary"This trial aims to see if barzolvolimab is effective, safe, and well-tolerated in adults with Chronic Spontaneous Urticaria who have not responded well to common
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial is comparing the effects of combining immunotherapy (pembrolizumab) with chemotherapy (doxorubicin) versus using chemotherapy alone to treat patients with undifferentiated pleomorphic sar
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Get notified when new Lazy Eye trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare two treatments for children aged 4 to 7 with lazy eye. One treatment involves watching special movies with a headset for 1 hour per day, 6 days a week
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if plozasiran injection is safe and effective in adults with high triglyceride levels. Participants will receive either plozasiran or a placebo every 3 months for a
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Summary"This trial will test a new injection called plozasiran in adults with very high levels of triglycerides. Participants will receive either plozasiran or a placebo every 3 months for a
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test the safety and effectiveness of plozasiran injection in adults with severe high levels of triglycerides. Participants will receive either plozasiran or a placebo every 3 months
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial compares two drugs, rituximab and mosunetuzumab, in treating patients with low tumor burden follicular lymphoma. Rituximab targets a protein found on B
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing the effectiveness of ZILRETTA in reducing pain in people with glenohumeral osteoarthritis when compared to a placebo. The secondary objectives include comparing the pain
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called pelacarsen to see if it is effective and safe for Black/African American and Hispanic individuals with heart disease and high levels of Lp(a). Participants
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare the overall survival of patients with certain types of advanced soft tissue sarcomas who have already tried 2 standard treatments, including one with anthracycline, with a new
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will investigate the impact of a single dose of SRP-9003 on beta-sarcoglycan gene expression in individuals with limb-girdle muscular dystrophy type 2E/R
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Idiopathic Pulmonary Fibrosis trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial is for people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis who have completed treatment with a medicine called BI 1015550 in a previous study. The goal is to see how
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if adding a monoclonal antibody called dinutuximab to standard treatments like chemotherapy and stem cell transplantation can help treat children with a type of cancer called high risk neuroblast
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
1
2
3
…50